Meeting NewsVideo

VIDEO: Eylea improves nonproliferative diabetic retinopathy in phase 3 study

VANCOUVER, British Columbia — Charles C. Wykoff, MD, PhD, discusses 24-week results of the phase 3 PANORAMA study regarding Eylea (aflibercept, Regeneron) for the treatment of nonproliferative diabetic retinopathy at the American Society of Retina Specialists meeting.

VANCOUVER, British Columbia — Charles C. Wykoff, MD, PhD, discusses 24-week results of the phase 3 PANORAMA study regarding Eylea (aflibercept, Regeneron) for the treatment of nonproliferative diabetic retinopathy at the American Society of Retina Specialists meeting.

    See more from American Society of Retina Specialists Meeting